v3.26.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock
ATM Program
Common Stock
Equity Offering
Common Stock
InnoCare Pharma Inc
Common Stock
Additional Paid-in Capital
ATM Program
Additional Paid-in Capital
Equity Offering
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
ATM Program
Equity Offering
InnoCare Pharma Inc
Total
Balance at the beginning at Dec. 31, 2024       $ 4     $ 699,651 $ 194 $ (387,391)       $ 312,458
Balance at beginning (in shares) at Dec. 31, 2024       41,793,412                  
Changes in Stockholders' Equity (Deficit)                          
Exercises of common stock options             99           99
Exercises of common stock options (in shares)       28,475                  
Stock-based compensation expense             5,386           5,386
Unrealized gain (loss) on investments               12         12
Foreign currency translation adjustment               (65)         (65)
Net loss                 (33,573)       (33,573)
Balance at end at Mar. 31, 2025       $ 4     705,136 141 (420,964)       284,317
Balance at end (in shares) at Mar. 31, 2025       41,821,887                  
Balance at the beginning at Dec. 31, 2024       $ 4     699,651 194 (387,391)       312,458
Balance at beginning (in shares) at Dec. 31, 2024       41,793,412                  
Changes in Stockholders' Equity (Deficit)                          
Unrealized gain (loss) on investments                         77
Foreign currency translation adjustment                         (340)
Net loss                         (137,295)
Balance at end at Sep. 30, 2025       $ 4     721,179 (69) (524,686)       196,428
Balance at end (in shares) at Sep. 30, 2025       42,213,465                  
Balance at the beginning at Mar. 31, 2025       $ 4     705,136 141 (420,964)       284,317
Balance at beginning (in shares) at Mar. 31, 2025       41,821,887                  
Changes in Stockholders' Equity (Deficit)                          
Exercises of common stock options             1,722           1,722
Exercises of common stock options (in shares)       266,810                  
Stock-based compensation expense             6,045           6,045
Unrealized gain (loss) on investments               30         30
Foreign currency translation adjustment               (265)         (265)
Net loss                 (52,223)       (52,223)
Balance at end at Jun. 30, 2025       $ 4     712,903 (94) (473,187)       239,626
Balance at end (in shares) at Jun. 30, 2025       42,088,697                  
Changes in Stockholders' Equity (Deficit)                          
Exercises of common stock options             664           664
Exercises of common stock options (in shares)       82,000                  
Stock-based compensation expense             7,336           7,336
Purchases of common stock under the employee Stock purchase plan             276           276
Purchases of common stock under the Employee stock purchase plan (in shares)       42,768                  
Unrealized gain (loss) on investments               35         35
Foreign currency translation adjustment               (10)         (10)
Net loss                 (51,499)       (51,499)
Balance at end at Sep. 30, 2025       $ 4     721,179 (69) (524,686)       196,428
Balance at end (in shares) at Sep. 30, 2025       42,213,465                  
Balance at the beginning at Dec. 31, 2025       $ 5     1,007,331 (64) (765,128)       $ 242,144
Balance at beginning (in shares) at Dec. 31, 2025       54,485,518                 54,485,518
Changes in Stockholders' Equity (Deficit)                          
Exercises of common stock options             367           $ 367
Exercises of common stock options (in shares)       25,767                  
Issuance of common stock   $ 1     $ 71,186 $ 93,644       $ 71,186 $ 93,645    
Issuance of common stock (in shares) 2,827,723 5,000,000                      
Stock-based compensation expense             9,195           9,195
Purchases of common stock under the employee Stock purchase plan             592           592
Purchases of common stock under the Employee stock purchase plan (in shares)       44,369                  
Unrealized gain (loss) on investments               (341)         (341)
Foreign currency translation adjustment               28         28
Net loss                 (80,987)       (80,987)
Balance at end at Mar. 31, 2026       $ 6     1,182,315 (377) (846,115)       335,829
Balance at end (in shares) at Mar. 31, 2026       62,383,377                  
Balance at the beginning at Dec. 31, 2025       $ 5     1,007,331 (64) (765,128)       $ 242,144
Balance at beginning (in shares) at Dec. 31, 2025       54,485,518                 54,485,518
Changes in Stockholders' Equity (Deficit)                          
Exercises of common stock options (in shares)                         712,572
Issuance of common stock (in shares)                   4,645,904      
Unrealized gain (loss) on investments                         $ (1,285)
Foreign currency translation adjustment                         89
Net loss                         (301,366)
Balance at end at Sep. 30, 2026       $ 7     1,280,055 (1,260) (1,066,494)       $ 212,308
Balance at end (in shares) at Sep. 30, 2026       67,795,055                 67,795,055
Balance at the beginning at Mar. 31, 2026       $ 6     1,182,315 (377) (846,115)       $ 335,829
Balance at beginning (in shares) at Mar. 31, 2026       62,383,377                  
Changes in Stockholders' Equity (Deficit)                          
Exercises of common stock options             806           806
Exercises of common stock options (in shares)       77,825                  
Vesting of restricted stock units (in shares)       119,545                  
Issuance of common stock           $ 14,063         $ 14,063    
Issuance of common stock (in shares)   750,000                      
Stock-based compensation expense             8,619           8,619
Unrealized gain (loss) on investments               (780)         (780)
Foreign currency translation adjustment               16         16
Net loss                 (111,456)       (111,456)
Balance at end at Jun. 30, 2026       $ 6     1,205,803 (1,141) (957,571)       247,097
Balance at end (in shares) at Jun. 30, 2026       63,330,747                  
Changes in Stockholders' Equity (Deficit)                          
Exercises of common stock options             7,904           7,904
Exercises of common stock options (in shares)       608,980                  
Vesting of restricted stock units (in shares)       4,951                  
Issuance of common stock     $ 1   $ 48,475         $ 48,475   $ 1  
Issuance of common stock (in shares) 1,818,181   2,000,000             1,818,181      
Stock-based compensation expense             17,276           17,276
Purchases of common stock under the employee Stock purchase plan             597           597
Purchases of common stock under the Employee stock purchase plan (in shares)       32,196                  
Unrealized gain (loss) on investments               (164)         (164)
Foreign currency translation adjustment               45         45
Net loss                 (108,923)       (108,923)
Balance at end at Sep. 30, 2026       $ 7     $ 1,280,055 $ (1,260) $ (1,066,494)       $ 212,308
Balance at end (in shares) at Sep. 30, 2026       67,795,055                 67,795,055